Smartest Doc
Symlin use helped patients with type 2 or type 1 diabetes achieve more time in normal glucose range Full Text
Amylin Pharmaceuticals, 06/12/2012
Amylin Pharmaceuticals, Inc. announced results from new analyses of previously completed clinical studies demonstrating that patients with type 2 or type 1 diabetes achieved a greater proportion of blood glucose measurements in the normal range when SYMLIN (pramlintide acetate) injection treatment was used along with insulin. Two abstracts highlighting the analyses evaluated the proportion of readings from self–monitored seven–point glucose profiles that fell above, below or within glycemic targets based on guidelines set by the American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE).